| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10020780 | HBV | ENSG00000135094.11 | protein_coding | SDS | No | No | 10993 | P20132 |
| TVIS10026977 | HBV | ENSG00000135094.11 | protein_coding | SDS | No | No | 10993 | P20132 |
| TVIS10024981 | HBV | ENSG00000135094.11 | protein_coding | SDS | No | No | 10993 | P20132 |
| TVIS10017160 | HBV | ENSG00000135094.11 | protein_coding | SDS | No | No | 10993 | P20132 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SDS |
|---|---|
| DrugBank ID | DB00133 |
| Drug Name | Serine |
| Target ID | BE0000164 |
| UniProt ID | P20132 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 14688104; 4377655; 500557 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Velayudhan J, Jones MA, Barrow PA, Kelly DJ: L-serine catabolism via an oxygen-labile L-serine dehydratase is essential for colonization of the avian gut by Campylobacter jejuni. Infect Immun. 2004 Jan;72(1):260-8.@@Snell K, Walker DG: Regulation of hepatic L-serine dehydratase and L-serine-pyruvate aminotransferase in the developing neonatal rat. Biochem J. 1974 Dec;144(3):519-31.@@Wong HC, Lessie TG: Hydroxy amino acid metabolism in Pseudomonas cepacia: role of L-serine deaminase in dissimilation of serine, glycine, and threonine. J Bacteriol. 1979 Oct;140(1):240-5. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | Serine and derivatives |
| SMILES | N[C@@H](CO)C(O)=O |
| Pathways | Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/18:0); Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/14:0); Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/15:0); Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z)); Glycine and Serine Metabolism; Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/16:0); Selenoamino Acid Metabolism; Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/15:0); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z)); Cystathionine beta-Synthase Deficiency; Sarcosine Oncometabolite Pathway; Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0); Phosphatidylethanolamine Biosynthesis PE(14:0/14:0); Globoid Cell Leukodystrophy; Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z)); Ammonia Recycling |
| PharmGKB | PA451330 |
| ChEMBL | CHEMBL11298 |
